Table 3.
Main outcomes of the original studies included in the systematic review
| Author | Main outcome | ||||
| 1. Prevalence | |||||
| Capaldo et al. [32] | Increasing trend in the prevalence of SM* in cystic fibrosis patients | ||||
| Psoter et al. [33] | No seasonal variation for SM* infection | ||||
| 2. Suggested risk factors | |||||
| Stanojevic et al. [12] | Lung function decline; younger age | ||||
| Graff et al. [13] | Oral antibiotics | ||||
| Talmaciu et al. [14] | Exposure to antibiotics; compromised clinical status | ||||
| Denton et al. [15] | Exposure to antibiotics; previous hospitalization | ||||
| Marchac et al. [16] | Exposure to antibiotics; exposure to oral steroids; Aspergillus fumigatus co-infection | ||||
| Paugam et al. [17] | Aspergillus fumigatus co-infection | ||||
| 3. SM* and Lung function | |||||
| Impact on lung function | No impact on lung function | Decrease in FEV1 | Increase in hospitalization, mortality, lung transplantation | Fungal co-infection | |
| Goss et al. [34] | x | ||||
| Dalbøge et al. [18] | x | x | |||
| Waters et al. [35] | x | ||||
| Waters et al. [19] | x | ||||
| Com et al. [20] | x | x | x | ||
| Cogen et al. [21] | x | x | |||
| Barsky et al. [22] | x | x | |||
| Poore et al. [23] | x | x | |||
| Berdah et al. [24] | x | x | |||
| 4. Genotype and phenotype heterogeneity of SM* | |||||
| Vidigal et al. [25] |
• High genotype and phenotype heterogeneity of SM* as expression of adaptability of the bacteria • No evidences about the impact of the heterogeneity on lung function |
||||
| Pompilio et al. [26] | |||||
| Esposito et al. [27] | |||||
| Alcaraz et al. [28] | |||||
| 5. Antimicrobial therapy against SM* | |||||
| Waters et al. [35] | Impact on lung function: | No impact of antibiotic therapy targeting SM during pulmonary exacerbations in patients with chronic SM infection did not affect the degree of FEV1 recovery or the time to subsequent exacerbation. | |||
| Esposito et al. [27] | Suggested antimicrobial drug: | Minocycline, doxycycline, trimethoprim-sulfamethoxazole | |||
| San Gabriel et al. [29] | Suggested antimicrobial drug: | Trimethoprim-sulfamethoxazole, ticarcillin-clavulanate, doxycycline | |||
| King et al. [30] | Suggested antimicrobial drug: | Aerosolized levofloxacin in chronic SM infections | |||
| Goss et al. [31] | Duration of antimicrobial therapy: | Same outcome** in acute exacerbation in CF patient for 10, 14 and 21-day regimens | |||
*SM: Stenotrophomonas maltophilia
**Outcome: FEV1 improvement